Bernhard R. M. Ehmer
Chairman at BIOTEST AG
Net worth: 94 515 $ as of 2024-03-30
Profile
Dr. Bernhard R.
M.
Ehmer, MD, is a Chairman-Supervisory Board at Biotest AG, an Independent Non-Executive Director at Achilles Therapeutics Plc and an Independent Member-Supervisory Board at Affimed NV.
He is on the Board of Directors at Achilles Therapeutics Plc, Affimed NV and Affimed GmbH.
Dr. Ehmer was previously employed as a Chairman by Symphogen A/S, a President by ImClone Systems Corp., a Managing Director & Senior Vice President by ImClone Systems International GmbH, a President & Chief Executive Officer by Neovii Biotech GmbH, a Chief Executive Officer & Managing Director by BioPheresis Technologies, Inc., a Chief Executive Officer & Managing Director by Biopheresis GmbH, a Head-Clinical Research & Development Operations by Merck KGaA, a Head-Therapeutics & Medical Operations by Boehringer Mannheim GmbH, and a VP, Head-Strategic Planning & Alliance Management by Merck KGaA.
He also served on the board at ADMA Biologics, Inc. and Hybrigenics SA. He received his undergraduate degree from Ruprecht-Karls-Universität Heidelberg and an undergraduate degree from Ludwig-Maximilians-Universität München.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AFFIMED N.V.
0.12% | 2023-03-14 | 17,833 ( 0.12% ) | 94 515 $ | 2024-03-30 |
Bernhard R. M. Ehmer active positions
| Companies | Position | Start |
|---|---|---|
| AFFIMED N.V. | Director/Board Member | 2016-01-20 |
| ACHILLES THERAPEUTICS PLC | Director/Board Member | 2022-05-03 |
| BIOTEST AG | Chairman | 2022-05-04 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Board Member | 2015-12-31 |
Former positions of Bernhard R. M. Ehmer
| Companies | Position | End |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Chairman | 2020-05-31 |
| BIOTEST AG | Chief Executive Officer | 2019-03-31 |
| ADMA BIOLOGICS, INC. | Director/Board Member | 2018-02-14 |
| ImClone Systems Corp. | President | 2014-09-30 |
ImClone Systems International GmbH
 ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 2011-12-31 |
Training of Bernhard R. M. Ehmer
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
| Ludwig-Maximilians-Universität München | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| MERCK KGAA | Health Technology |
| ADMA BIOLOGICS, INC. | Health Technology |
| AFFIMED N.V. | Health Technology |
| BIOTEST AG | Health Technology |
| ATON | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Private companies | 8 |
|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Biopheresis GmbH
 Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The private company is based in Heidelberg, Germany. | Commercial Services |
BioPheresis Technologies, Inc.
 BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
| Boehringer Mannheim GmbH | |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
| ImClone Systems Corp. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
- Stock Market
- Insiders
- Bernhard R. M. Ehmer
